

1 **Specific Dynamic Variations in the Peripheral Blood Lymphocyte Subsets in**
2 **COVID-19 and Severe Influenza A Patients: A Retrospective Observational**
3 **Study**

4 **Running title:** Change of Lymphocyte in COVID-19 and Influenza A Patients

5

6 Fang Qian^{1#}, Guiju Gao^{1#}, Yangzi Song^{1#}, Yanli Xu^{1#}, Aibin Wang¹, Sa Wang¹, Yiwei,
7 Hao⁴, Meiling Chen⁴, Xiaoyang Ma³, Tianwei Zhao¹, Xiaodi Guo², Zhihai Chen^{1*},
8 Fujie Zhang^{1*}

9 1. Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital
10 Medical University

11 2. Department of Oncology, Beijing Ditan Hospital, Capital Medical University

12 3. Department of Neurology, Beijing Ditan Hospital, Capital Medical University

13 4. Department of Medical Records and Statistics, Beijing Ditan Hospital, Capital
14 Medical University

15 #: These authors contributed equally to this work

16

17 *: Corresponding Author

18 Fujie Zhang MD.& PhD. Director and Professor of Medicine Clinical and Research
19 Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical
20 University.No.8, Jing shun Dong jie, Chaoyang District Beijing 100015, China

21 treatment@chinaaids.cn

22 Tel: 86-13001953958

23 Zhihai Chen

24 Professor of Medicine Clinical and Research Center of Infectious Diseases, Beijing

25 Ditan Hospital, Capital Medical University, No.8 Jing shun Dong jie, Chaoyang

26 District Beijing 100015, China

27 Email: chenzhihai0001@126.com

28 Tel: 86-13501340403

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45 **Abstract:**

46 **Background:**

47 Both COVID-19 and influenza A contribute to increased mortality among the elderly
48 and those with existing comorbidities. Changes in the underlying immune
49 mechanisms determine patient prognosis. This study aimed to analyze the role of
50 lymphocyte subsets in the immunopathogenesis of COVID-19 and severe influenza A,
51 and examined the clinical significance of their alterations in the prognosis and
52 recovery duration.

53 **Methods:**

54 By retrospectively reviewing of patients in four groups (healthy controls, severe
55 influenza A, non-severe COVID-19 and severe COVID-19) who were admitted to
56 Ditan hospital between 2018 to 2020, we performed flow cytometric analysis and
57 compared the absolute counts of leukocytes, lymphocytes, and lymphocyte subsets of
58 the patients at different time points (weeks 1- 4).

59 **Results:**

60 We reviewed the patients' data of 110 healthy blood donors, 80
61 Non-severe-COVID-19, 19 Severe-COVID-19 and 43 severe influenza A. We found
62 total lymphocytes ($0.93 \times 10^9/L$, $0.84 \times 10^9/L$ vs $1.78 \times 10^9/L$, $P < 0.0001$) and
63 lymphocyte subsets (T cells, $CD4^+$ and $CD8^+$ T cell subsets) of both severe patients to
64 be significantly lower than those of healthy donors at early infection stages. Further,
65 significant dynamic variations were observed at different time points (weeks 1–4).

66 **Conclusions:**

67 Our study indicates lymphopenia to be associated with disease severity and suggests
68 the plausible role of lymphocyte subsets in disease progression, which in turn affects
69 prognosis and recovery duration in patients with severe COVID-19 and influenza A.

70

71 **Key words:** Coronavirus disease-19 (COVID-19); Severe influenza A; Lymphocyte;
72 T cells subsets.

73

74 **Background**

75 Since the time the World Health Organization (WHO) declared the infection caused
76 by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus
77 Disease 2019 (COVID-19), a global pandemic, has seriously threatened to global
78 public health and is still expanding. The clinical manifestations of COVID-19 can be
79 mild or severe, which the incidence of mortality is higher among the elderly and
80 among those with pre-existing comorbidities, including hypertension, cardiovascular
81 and cerebrovascular disease, and diabetes, similar to influenza.[1] In addition, their
82 modes of transmission are by contact, droplets, or fomites.[2,3] While relatively little
83 is known about the immunopathological aspects of SARS-CoV-2 virus, there exists
84 vast literature on the possible underlying mechanisms of disease pathogenesis of
85 Influenza A virus.

86 As previous studies demonstrated that infection of humans with influenza A virus
87 leads to an induction of apoptosis of a portion of CD3⁺, CD4⁺, CD8⁺, and
88 CD19⁺ lymphocytes, thus resulting in a severe transient leukopenia, and that
89 lymphocyte apoptosis, which represents a part of an overall beneficial immune
90 response could be a possible mechanism of disease pathogenesis.[4,5]

91 Although the precise immunopathogenesis of COVID-19 is unknown, genome studies
92 and standard blood investigations suggest involvement of the immune
93 system. Previous studies have shown that severe leukopenia and lymphopenia occur
94 during early stages of infection and subsequently become less prominent as the
95 disease progresses in patients with severe COVID-19.[6,7]Furthermore, as

96 lymphopenia developed in severe COVID-19 cases, it was shown to be a predictor of
97 prognosis and a reliable indicator of disease severity and hospitalization
98 in COVID-19 patients.[8]However, data on kinetic alterations in lymphocytes after
99 COVID-19 infection are sparse. To the best of our knowledge, there are no
100 comparative studies focusing on the dynamic variations in lymphocyte subsets of
101 patients with influenza A and SARS-Cov-2 infections. Whether changes in the
102 underlying immune mechanisms determine patient prognosis and recovery in
103 COVID-19 remains unclear. Therefore, in view of the above, in this retrospective
104 study, we analyzed the role of lymphocytes and lymphocyte subsets in the
105 immunopathogenesis of COVID-19 and severe influenza A, to provide us with
106 valuable insights for better understanding of the underlying immune mechanisms
107 following SARS-Cov-2 and severe influenza A infections.

108

109 **Methods**

110 **Study design and participants**

111 We retrospectively reviewed the clinical data of all patients who were confirmed to
112 have COVID-19 and were admitted to the Beijing Ditan Hospital from January 20,
113 2020 to March 17, 2020. In addition, all patients with severe influenza A who were
114 admitted to Ditan hospital between 2018 to 2020 were recruited for this study. A
115 group of healthy blood donors who were previously recruited in 2018 were used to
116 provide data for the healthy controls in this study. This study was approved by the
117 Ethics Committee of Beijing Ditan Hospital (No. 202000601). The need for

118 individual consent was waived because of the retrospective nature of the study.

119 The patients with COVID-19 were divided into non-severe and severe pneumonia
120 groups according to the Diagnosis and Treatment Protocols for Patients with
121 COVID-19 (Trial Version 7, Revised).[9]The diagnostic criteria for patients with
122 non-severe COVID-19 included: (1) Epidemiological history, (2) Fever or other
123 respiratory symptoms, (3) Typical computed tomography (CT) image abnormalities of
124 viral pneumonia, and (4) Positive result of reverse transcription-polymerase chain
125 reaction (RT-PCR) for SARS-CoV-2 Ribonucleic acid (RNA), while those with
126 severe COVID-19 additionally met at least one of the following conditions: (1)
127 Shortness of breath or dyspnea, with a respiratory rate of 30 times/min, (2) Oxygen
128 saturation (resting state) 93%, or (3) PaO₂ / FiO₂ 300 mmHg.

129 Samples of patients with COVID-19 that were SARS-CoV-2 positive based on nucleic
130 acid detection and showed the presence of lymphocyte subset population for
131 approximately four weeks after onset, where lymphocyte subset analyses were
132 performed at least twice within the four weeks duration, were included in this study.
133 However, those samples that were SARS-CoV-2 nucleic acid positive and either
134 lacked or showed the presence of only one lymphocyte subset population for
135 approximately four weeks after onset were not considered for this study.

136 Patients with severe influenza were diagnosed based on Influenza: Diagnosis and
137 Treatment (2019).[10]The diagnostic criteria were as follows: sustained high fever>3
138 days accompanied by severe cough, coughing up sputum or bloody sputum, or chest
139 pain; rapid breathing rate, respiratory distress, and cyanosis of lips; change in

140 consciousness such as unresponsiveness, drowsiness, restlessness, or convulsions;
141 Severe vomiting, diarrhea, dehydration; presence of symptoms associated with
142 pneumonia; exacerbation of pre-existing conditions and/or diseases; other clinical
143 conditions requiring hospitalization. Patients with severe influenza A admitted to our
144 hospital who met the above criteria were included in this study. Patients were
145 excluded if an alternative diagnosis, such as the presence of influenza B,
146 parainfluenza, respiratory syncytial virus, adenovirus, mycoplasma, chlamydia,
147 legionella was determined.

148 Healthy controls who tested negative for human immunodeficiency virus (HIV)
149 infection, hepatitis viral infections, systemic infections, connective tissue diseases,
150 cancer, or any other abnormal tumor markers were considered.

151 Patients in four groups (non-severe COVID-19 and severe COVID-19, severe
152 influenza A, and healthy controls) excluded minors younger than eighteen years old
153 and pregnant women.

154 ***Data collection***

155 The information related to age, gender, onset of symptoms, medical history of
156 pre-existing comorbidities (hypertension, diabetes, chronic obstructive pulmonary
157 disease (COPD), cardiovascular disease, chronic kidney disease, and/or autoimmune
158 disease), severity assessment on admission, laboratory findings, and treatment
159 regimen for each patient was extracted from electronic medical records.

160 ***Laboratory confirmation***

161 Laboratory confirmation tests for COVID-19 were performed by Beijing Center for

162 Disease Control and Prevention (CDC) and Beijing Ditan Hospital. Throat swab
163 and/or sputum specimens were collected from all patients at admission and were
164 tested the same day. Patients were confirmed to be positive for SARS-CoV-2 nucleic
165 acid by real-time fluorescent reverse transcriptase-polymerase chain reaction assay,
166 according to the WHO interim guidance for COVID-19.[11]

167 The diagnosis of severe influenza virus infection was confirmed by RT-PCR of
168 nasopharyngeal swabs.[10]

169 *Flow cytometric analyses*

170 To explore the cellular immune response of patients with severe and non-severe
171 COVID-19 and severe influenza A, peripheral blood samples (2mL each) were
172 collected from healthy controls and all patients at week 1 (0-7 days), week 2 (8-14
173 days), week 3 (15-21 days), and week 4 (22-28 days) from the initial onset of
174 symptoms, for analyses of complete blood cell counts and cell counts of lymphocyte
175 subsets (CD4⁺ T cell, CD8⁺ T cell, B cell, and natural killer (NK) cell counts [cells/ μ L]
176 and CD4⁺ T/CD8⁺ T ratio). Lymphocyte subsets were detected and counted by BD
177 FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), and the subsets
178 were characterized according to phenotypes of the corresponding CD antigens.

179 For T cell subset identification and counting, a Four ColorHuman
180 CD3/CD8/CD45/CD4 Flow Kit was employed, according to manufacturer's
181 instructions. Briefly, 50 μ L of the isolated peripheral blood mononuclear cells was
182 incubated directly with the Four Color reagent consisting of a combination of
183 RPE-Cy5.5 conjugated CD3 (Mouse IgG1), APC conjugated CD8 (Mouse IgG1),

184 RPE conjugated CD45 (Mouse IgG2a), and fluorescein isothiocyanate
185 (FITC)-conjugated CD4 (mouse IgG1) monoclonal antibodies for 15 min at 4°C in
186 absolute counting tubes. Subsequently, 450 µL of red blood cell lysing solution (1xBD
187 lysing solution) was added to the tubes before performing the flow cytometric
188 analysis. The samples were then incubated at room temperature for 5 min prior to
189 detection by BD FACS Calibur flow cytometer. Data were obtained and analyzed
190 automatically by the MultiSET software.

191 **Statistical analyses**

192 All analyses were performed using SPSS statistical software (version 26.0, IBM,
193 Armonk, NY, USA). Categorical data are expressed in frequency or percentage, and
194 statistical significance was determined by χ^2 or Fisher's exact test. Nonparametric
195 variables are expressed as median with interquartile range (IQR). For continuous data,
196 Mann-Whitney U test or Kruskal Wallis test was performed to compare variables
197 between different groups and determine the statistical significance. In all analyses, P
198 < 0.05 was statistically significant. The dynamic changes of different subsets of
199 lymphocytes at different time periods are represented by boxplots.

200

201 **Results**

202 *Demographic and clinical characteristics of patients with COVID-19 and severe* 203 *influenza A*

204 In our study, we retrospectively reviewed the clinical data of 110 healthy blood
205 donors (healthy controls), 99 patients with COVID-19 and 43 patients with severe

206 influenza A. The group with healthy controls (HC) comprised of 53 males (48%) and
207 57 females (52%). Among the 99 patients with COVID-19, 56 were men (56.6%) and
208 43 were women (43.4%). All the COVID-19 patients were divided into two groups,
209 according to the abovementioned diagnostic criteria, and there were 80 non-severe
210 cases (80.8%) and 19 severe cases (19.2%; Table 1). The median age of patients with
211 non-severe and severe COVID-19 was 37 (30–49) years and 67 (53–74) years,
212 respectively. The severe patient group had a higher age than the non-severe
213 COVID-19 group. The median durations of hospitalization of patients with
214 non-severe and severe COVID-19 were 4 (2, 7) and 5 (4.5, 10) days, respectively.
215 All the patients with severe COVID-19 (n = 19, 100%) presented with fever, cough,
216 and dyspnea. On the contrary, only a few patients with non-severe COVID-19 had
217 fever (n = 58, 73%) and cough (n = 38, 48%). Notably, none of them had dyspnea.
218 A total of 31 (31.3%) patients in both the COVID-19 groups had pre-existing chronic
219 medical conditions, including diabetes (8 [11%]), hypertension (24 [32.9%]), COPD
220 (2 [2.8%]), cardiovascular disease (2 [2.8%]), renal disease (1 [1.4%]), and
221 autoimmune disorders (5 [6.9%]). Specifically, 19 patients (24%) with non-severe
222 COVID-19 and 12 patients (63%) with severe COVID-19 presented with one or more
223 of the pre-existing chronic medical conditions (Table 1). One patient in the severe
224 COVID-19 group died on day 28 after the onset of the disease.
225 Similar to the group with severe COVID-19, the median age of patients with severe
226 influenza A infection was higher (70 years) than that of those of healthy controls (45
227 years). Notably, the difference in age was found to be statistically significant ($P <$

228 0.05) between the groups. All patients with severe influenza A infection (n = 43,
229 100%) presented with fever and cough. However, only 33 patients (77%) had dyspnea.
230 Out of 43 patients with severe influenza A, 4 (9%) died and 39 (91%) survived (Table
231 1).

232 *Variations in leukocyte populations in COVID-19 and severe influenza A*

233 We analyzed different variations in leukocyte subpopulations of patients with
234 non-severe and severe COVID-19 and severe influenza A during the first week of
235 illness. The absolute counts of total white blood cells (WBCs) of patients with
236 non-severe ($5.34 \times 10^9/L$, $P < 0.001$) and severe COVID-19 ($3.92 \times 10^9/L$, $P < 0.0001$)
237 were significantly lower than those of the healthy donors ($6.01 \times 10^9/L$; Table 2).
238 Moreover, a statistically significant difference was observed between WBC counts of
239 patients with non-severe and that of those with severe COVID-19 ($P = 0.049$). Further,
240 there was a significant difference between the WBC counts of patients with severe
241 influenza A and those of patients with severe COVID-19 ($P = 0.027$).

242 Expectedly, the absolute counts of lymphocytes in healthy donors ($1.78 \times 10^9/L$) were
243 significantly higher than those of patients with non-severe COVID-19 ($1.51 \times 10^9/L$, P
244 = 0.027), severe COVID-19 ($0.93 \times 10^9/L$, $P < 0.0001$), and severe influenza A (0.84
245 $\times 10^9/L$, $P < 0.0001$) during the first week of illness (Table 2). Further, there was a
246 significant difference in the absolute lymphocyte counts of patients with non-severe
247 and severe COVID-19 ($P < 0.0001$).

248 *Distinct alterations in peripheral lymphocyte subsets in COVID-19 and severe* 249 *influenza A*

250 To further determine variations in different lymphocyte subsets in peripheral blood
251 samples of patients with non-severe COVID-19, severe COVID-19, and severe
252 influenza A during the first week of illness, we performed flow cytometric analysis to
253 enumerate total T cell population, CD4⁺ and CD8⁺ T cell subsets, B cells and NK cells.
254 Similar to the findings of the absolute counts of total lymphocytes, patients with
255 severe COVID-19 and severe influenza A had a significantly lower number of total T
256 cells ($P = 0.001$ and $P < 0.0001$, respectively), CD4⁺ T cells ($P = 0.001$ and P
257 < 0.0001 , respectively), and CD8⁺ T cells ($P = 0.001$ and $P < 0.0001$, respectively)
258 than healthy controls.

259 Notably, there was a significant difference between the CD8⁺ T cell subset ($P = 0.036$)
260 counts of patients with non-severe COVID-19 and those of healthy donors. The
261 differences in the total T cell population ($P < 0.0001$), CD4⁺ T cell subset ($P = 0.001$),
262 and CD8⁺ T cell subset ($P = 0.001$) of patients with non-severe and severe COVID-19
263 were statistically significant (Table 2).

264 In addition, the median of CD4⁺/CD8⁺ ratio in non-severe COVID-19, severe
265 COVID-19 and severe influenza group showed no different compared to HCs ($P = 0.$
266 242 , $P = 0.221$ and $P = 0.651$, respectively). And at the same time, the median NK cells
267 of non-severe and severe COVID-19 patients showed no difference compared to HCs
268 ($P = 0.514$ and $P = 0.355$, respectively). There was no significant difference in B cells
269 between the severe and non-severe COVID-19 groups ($P = 0.093$). (Table 2)

270 *Dynamic changes in leukocyte and lymphocyte subset counts with disease*
271 *progression and assessment of severity*

272 As shown in Table 2, total WBCs, the absolute lymphocytes, total T cells, CD4⁺ and
273 CD8⁺ T cell subsets in the peripheral blood samples of all patients were found to be
274 lower than those of healthy donors at the time of disease onset. To further determine
275 significant changes in the immune cell subsets of patients with non-severe COVID-19,
276 severe COVID-19, and severe influenza A, with disease evolution, we compared the
277 absolute counts of leukocytes, total lymphocytes, and lymphocyte subsets of the three
278 patient groups at weeks 1, 2, 3, and 4.

279 Unlike other groups, in patients with severe COVID-19, leukocyte counts gradually
280 increased from week 1 to week 4, despite being lower than the normal. Notably, the
281 variations in leukocyte counts were found to be statistically significant. (W1-W2: $P =$
282 0.013 , W1-W3: $P = 0.003$, W1-W4: $P = 0.001$). A similar trend was observed with
283 total lymphocyte count, which sharply increased at week 3, showing a significant
284 difference compared to those at weeks 1 and 2 (W1-W3: $P = 0.013$, W1-W4: P
285 $= 0.002$, W2-W3: $P = 0.001$) (**Fig. 1 A, B**). On the other hand, a significant and a
286 drastic increase was noted in the cell counts of total T cell and CD4⁺ T cell subset at
287 week 4 when compared with those of weeks 1 and 2. (W1-W4: $P = 0.034$, W2-W4: P
288 $= 0.003$; W1-W4: $P = 0.020$, W2-W4: $P = 0.001$) (**Fig. 1 C- E**).

289 Consistent with the findings of patients with severe COVID-19, the leukocyte counts
290 of patients with non-severe COVID-19 were significantly higher in week 3 than those
291 of week 1 and week 2 (W1-W3: $P = 0.005$, W2-W3: $P = 0.044$). A similar tendency
292 was seen with lymphocyte count, which showed a sharp significant increase at week 3
293 compared with that seen at week 1 (W1-W3: $P = 0.004$). Interestingly, a significant

294 change in total T cell count was observed at week 3, suggesting a marked increase in
295 total T cell population when compared with that observed at week 2 (W2-W3: $P =$
296 0.045)(**Fig. 1 A-C**).The differences in the absolute counts of total lymphocytes, total T
297 cells, CD4⁺ and CD8⁺ T cell subsets were found to be significant between the severe
298 and non-severe COVID-19 groups at all time points (weeks 1 through 4), although
299 they were visibly lower than those of healthy controls (**Fig. 1 B-E**).When compared
300 with healthy controls, no significant changes were seen in B cell populations and
301 CD4⁺/CD8⁺ ratios of patients with severe and non-severe COVID-19 during the four
302 weeks following the infection (**Fig. 1 F, H**).Interestingly, the NK cell counts of patients
303 with severe and non-severe COVID-19 gradually increased from weeks 2 to 4. These changes
304 were found to be statistically significant (W2-W4: $P = 0.011$ and $P = 0.042$, respectively) (**Fig.**
305 **1 G**).On the contrary, in patients with severe influenza A infection, significant changes were
306 only evident in the cell counts of total T cells, CD4⁺ and CD8⁺ T cell subsets (W1-W2: $P =$
307 0.003, $P = 0.006$, and $P = 0.030$, respectively) (**Fig.1 C- E**).

308

309 **Discussion**

310 In this study, we aimed to analyze the role of lymphocyte subsets in the
311 immunopathogenesis of COVID-19 and severe influenza A, and examined the clinical
312 significance of their alterations, especially in determining the prognosis and recovery
313 duration. Our analyses revealed significant dynamic variations in total lymphocytes
314 and lymphocyte subsets, which get activated in the early stages of COVID-19 and
315 severe influenza A infections, and further demonstrated that severe immune injury

316 tended to be more prominent in patients with severe form of the disease. The recovery
317 rate of patients with severe COVID-19 was comparatively longer than those who
318 received immediate antiviral treatment for severe influenza A and those with
319 non-severe COVID-19.

320 We retrospectively reviewed the clinical data of 99 patients who were confirmed to
321 have COVID-19, 43 patients with severe influenza A and 110 healthy blood donors
322 who were previously recruited in 2018. All the patients with COVID-19 were divided
323 into two groups, according to the abovementioned diagnostic criteria, including 80
324 non-severe cases (80.8%) and 19 severe cases (19.2%). Several reports and studies
325 have clearly indicated that older or elderly people are more prone to COVID-19 as
326 their immune systems are likely to get overwhelmed by infections due to their
327 advanced age. Similarly, the elderly who are 65 years or older are particularly at risk
328 for influenza infection, hospitalization, and death due to influenza-related
329 complications, such as pneumonia.[12] In our study, the median age of patients with
330 non-severe COVID-19 was 37 years, while that of those with severe COVID-19 was
331 67 years. Consistent with the previous studies, our data indicate that the ages of the
332 severe patient group are higher than those of the non-severe COVID-19 group.
333 Further, our study showed that the median age of patients with severe influenza A
334 infection was higher (70 years) than that of those with non-severe COVID-19 (37
335 years) and healthy controls (45 years). Notably, this difference in age was found to be
336 statistically significant ($P < 0.05$) among the groups, which suggests that the elderly
337 people represent a large at-risk population.

338 The WHO-China joint report on COVID-19 provided a comprehensive
339 symptomatology of COVID-19 (n = 55,924)[13].A previous study showed that
340 patients with COVID-19 present with pyrexia in 85% of cases during their illness
341 course, but only 45% are febrile on early presentation. In addition to cough (67.7%)
342 and sputum (33.4%), respiratory symptoms, such as dyspnea, sore throat, and nasal
343 congestion were reported to be present in 18.6%, 13.9%, and 4.8% of cases,
344 respectively. Both COVID-19 and influenza present with common clinical
345 manifestations including fever, cough, rhinitis, sore throat, headache, dyspnea, and
346 myalgia. [7,14,15]In our study, all the patients with severe COVID-19 presented with
347 fever, cough, and dyspnea, whereas only 73% and 48% of patients with non-severe
348 COVID-19 had fever and cough, respectively. Similar to the severe COVID-19 group,
349 all patients with severe influenza A infection presented with fever and cough.
350 However, only 77% of the patients had dyspnea. These clinical manifestations of
351 COVID-19 and influenza infections were consistent with other studies. As previously
352 reported the mortality rate also increases in patients with additional comorbidities.[3]
353 Specifically, 63% and 84% patients with severe COVID-19 and severe influenza A,
354 respectively, presented with one or more pre-existing chronic medical conditions.
355 While the mortality rate was 5% due to severe COVID-19, it was even higher (9%)
356 for severe influenza A.

357 Lymphocytes and their subsets play a crucial role in maintaining immune homeostasis and
358 inflammatory response in the host. As in case of immune disorders and other infections, a
359 viral infection impairs the host's immune defenses and results in decreased levels of

360 lymphocytes and their subsets.[16,17] Lymphocyte subsets, namely CD4⁺ T cells, CD8⁺ T
361 cells, B cells, and NK cells are primarily involved in the humoral and cytotoxic immunity
362 against viral infection. Therefore, this necessitates the need to understand the mechanism of
363 reduced blood lymphocyte levels and characterize the dynamic alterations of lymphocyte
364 subsets to provide novel insights for an effective treatment and prognosis of COVID-19. As
365 lymphopenia is frequently observed during the initial stages of respiratory viral
366 infection.[3,18] We identified and analyzed different variations in leukocytes, lymphocytes,
367 and lymphocyte subsets in patients with non-severe and severe COVID-19 and severe
368 influenza A during the first week of illness. Our results showed that the absolute counts of
369 total WBCs and lymphocytes of patients with non-severe ($5.34 \times 10^9/L$, $P < 0.001$ and 1.51
370 $\times 10^9/L$, $P = 0.027$, respectively) and severe COVID-19 ($3.92 \times 10^9/L$, $P < 0.0001$ and 0.93
371 $\times 10^9/L$, $P < 0.0001$, respectively) were significantly lower than those of healthy donors (6.01
372 $\times 10^9/L$ and $1.78 \times 10^9/L$, respectively). Further, the total lymphocyte counts of patients with
373 severe influenza A were comparatively lower than those of healthy donors, ($0.84 \times 10^9/L$, $P <$
374 0.0001). These findings are corroborated by a previous study which hypothesized that the
375 virus might directly infect lymphocytes resulting in their apoptosis, thus leading to causing a
376 sharp decline in total lymphocyte population and subsequent lymphopenia. Moreover,
377 lymphocytes express the coronavirus receptor angiotensin-converting enzyme 2 (ACE-2),
378 and therefore are a direct target for the virus.[19] Another retrospective study suggested that
379 lymphopenia might be one of the predictive factors for progression to respiratory failure
380 during early stages following Middle East Respiratory Syndrome coronavirus
381 (MERS-Cov) infection.[20] Giving further strength to our study, a study by Geng et al.

382 demonstrated the decline in the populations of T lymphocytes and their subsets, after
383 influenza A virus infection, to be positively correlated with prognosis.[21] We further
384 performed flow cytometric analysis to enumerate total T cell population, CD4⁺ and CD8⁺ T
385 cell subsets, B cells and NK cells in patients with non-severe COVID-19, severe COVID-19,
386 and severe influenza A to determine significant changes in different lymphocyte subsets
387 during their first week of illness. Our study demonstrated that patients with severe COVID-19
388 and severe influenza A had a significantly lower number of total T cells ($P = 0.001$ and P
389 <0.0001 , respectively), CD4⁺ T cell subsets ($P = 0.001$ and $P <0.0001$, respectively), and
390 CD8⁺ T cell subsets ($P = 0.001$ and $P <0.0001$, respectively) than healthy controls. Further,
391 significant differences in total WBCs ($P = 0.049$), total lymphocytes ($P < 0.0001$) total T cell
392 population ($P < 0.0001$), CD4⁺ T cell subsets ($P = 0.001$), and CD8⁺ T cell subsets ($P =$
393 0.001) were observed between patients with non-severe and severe COVID-19. Notably, there
394 was a significant reduction in CD8⁺ T cell subsets ($P = 0.036$) in patients with non-severe
395 COVID-19 compared with healthy controls. This indicates a more obvious change in CD8⁺ T
396 cell subsets than in other lymphocyte subsets following SARS-CoV-2 infection. Therefore,
397 our results reiterate the fact that CD8⁺ T cell responses play a major role in antiviral
398 immunity.[22] Taken together, lymphopenia was common in the patients with COVID-19,
399 indicating a significant impairment in the host's immune system following SARS-CoV-2 and
400 influenza A infections. Our findings are in line with other studies which also detected these
401 alterations in patients with pneumonia caused by MERS-CoV and Severe acute respiratory
402 syndrome coronavirus (SARS-CoV).[20, 23] In addition, a significant reduction in both
403 CD4⁺ T cells and CD8⁺ T cells were specifically observed in patients with severe COVID-19

404 and severe influenza A. Therefore, this indicates a more severe immune insult in patients with
405 the severe form of the disease. Consequently, the alteration would be more profound, and
406 leads to adverse clinical outcome in these patients. Thus, lymphocytes and their subsets,
407 especially CD8⁺ T cells, might be a potential predictor for disease severity and clinical
408 efficacy in COVID-19.

409 Next, we focused on the dynamics of T lymphocytes and their subsets, which played a
410 vital role in cellular immune responses. We compared the absolute counts of
411 leukocytes, total lymphocytes, and lymphocyte subsets of the non-severe and severe
412 COVID-19 patient groups at weeks 2, 3, and 4 with that of those observed during the
413 initial stages of infection. The total leukocyte, lymphocyte, and T cell counts
414 significantly improved at week 3 in patients with non-severe COVID-19. Lymphocyte
415 also recovered markedly at week 3 in severe COVID-19 patients. However, T cell and
416 CD4⁺ T cell subset population significantly increased at week 4 in patients with
417 severe COVID-19. Our results are consistent with a previous study by He et al. that
418 showed a sharp decline (below normal) in the cell counts of CD45⁺, CD3⁺ T cell
419 subsets, CD4⁺ T cell subsets, and CD8⁺ T cell subsets during the first week of
420 SARS-Cov infection; their values further declined during the second week before
421 increasing during the third week and returning to normal by the fifth week. Moreover,
422 CD4⁺ T and CD8⁺ T cell counts were found to be extremely low in critically ill and
423 deceased patients.[23] Taken together, the alterations in lymphocytes and their subsets
424 gradually improved at later time points in patients with COVID-19. Collectively, our
425 results indicate that the recovery duration of patients with severe COVID-19 is longer

426 than those with the mild form of the disease.

427 Our study results further revealed a noticeable difference in the time taken for the cell
428 counts to improve among the severe and non-severe COVID-19 and the severe
429 influenza groups. The cell counts of total lymphocytes and their subsets recovered
430 only around week 4 in severe COVID-19; the recovery time was almost delayed by a
431 week compared with those having non-severe COVID-19. On the contrary, the cell
432 counts of total lymphocytes and their subsets in patients with severe influenza A
433 increased and improved drastically at week2; this rapid recovery rate could be
434 attributed to the early initiation of treatment with the neuraminidase inhibitor,
435 oseltamivir, or peramivir, which interfere with virus release from host cells by
436 blocking the viral nucleic acid function, thus preventing infection of new host
437 cells.[24]

438 NK cells are cytotoxic innate lymphocytes that play an important role in controlling
439 the viral burden. NK cell responses can be specific, and they interact with both innate
440 and adaptive immune cells to coordinate appropriate antiviral responses.[25] Although
441 we observed a reduction in NK cell counts during the initial stages of infection in
442 patients with severe and non-severe COVID-19, their recovery rate (cell counts
443 improved at week 3) showed a similar trend as that of the lymphocytes in both the
444 groups. One plausible reason for this observation could be that the NK cell cross-talk
445 might have got suppressed following the virus attack, which might have further led to
446 impairment of CD4⁺ T cell responses and their effects on CD8⁺ T cells. This is further
447 supported by a finding from this study which demonstrated a significant reduction in

448 CD4⁺ T cell subsets, especially in patients with severe COVID-19. Given the role of
449 B cells in adaptive immune response, we did not observe any significant changes in
450 total B cell population in all patients with COVID-19 during the course of illness.
451 This could possibly be attributed to the poor activation of the adaptive immune
452 response against the virus. Moreover, the lack of detectable virus during stage I
453 (asymptomatic incubation period)of the SARS-CoV-2 infection might have failed to
454 elicit protective B cell immunity.[26]Therefore, future research focusing on strategies
455 to enhance the specific adaptive immune responses during the incubation and
456 non-severe stages of the SARS-CoV-2 infection could significantly boost the B cell
457 population, preventing the progression to the stage III severe respiratory symptomatic
458 stage with high viral load. Furthermore, studies identifying specific immune
459 components or functions that limit protective immunity to virus infection are
460 warranted.

461 Our study has several limitations. This study was retrospective, small single-center
462 study and only included a small sample of 99 patients with COVID-19 admitted to
463 Beijing Ditan Hospital, which may confound the results and potentially introduce
464 selection bias. This may limit the generalizability of the study. In addition,
465 inconsistencies in time periods between illness onset and admission might have led to
466 missing data which could result in observation biases in the dynamic variations in
467 immune cells.

468 **Conclusions**

469 Collectively, our study indicates that lymphopenia might be associated with disease

470 severity and suggests the plausible role of lymphocyte subsets in disease progression,
471 which in turn affects prognosis and recovery duration in patients with severe
472 COVID-19 and influenza A. The dynamic alterations in lymphocytes and their subsets
473 provides valuable insights into the immunopathogenesis of disease progression in
474 COVID-19.

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492 **Abbreviations**

493 COVID-19: Coronavirus disease-19

494 WHO: World Health Organization

495 SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

496 CT: Computed tomography

497 RT-PCR: Reverse transcription-polymerase chain reaction

498 RNA : Ribonucleic acid

499 HIV: human immunodeficiency virus

500 COPD: chronic obstructive pulmonary disease

501 CDC: Center for Disease Control and Prevention

502 NK: natural killer

503 IQR: interquartile range

504 HC: healthy controls

505 WBC: White blood cells

506 LY: Lymphocytes

507 ACE-2: angiotensin-convertingenzyme 2

508 MERS- CoV: Middle East Respiratory Syndrome coronavirus

509 SARS-CoV: Severe acute respiratory syndrome coronavirus

510

511

512

513

514 **Declarations**

515 *Ethics approval and consent to participate*

516 This study was approved by the Ethics Committee of Beijing Ditan Hospital (No.
517 202000601). The need for individual consent was waived because of the retrospective
518 nature of the study.

519 *Consent for publication*

520 Not applicable.

521 *Availability of data and material*

522 The datasets used and/or analysed during the current study are available from the corr
523 esponding author on reasonable request.

524 *Competing interests*

525 The authors declare that they have no competing interests.

526 *Funding*

527 None.

528 *Authors' contributions*

529 FZ and ZC were responsible for the study concept and design. They had complete
530 access to all the data in this study and take responsibility for data integrity and
531 accuracy of the data analysis. FQ and YS contributed to the writing of this manuscript.
532 FQ, GG, YX, AW, SW, XM, TZ and XG contributed to the sample acquisition of
533 patients, diagnosis, and treatment. FQ and YS contributed to data collection, data
534 interpretation, and analysis of the results. YH and MC conducted the statistical
535 analyses. All authors reviewed and approved the final manuscript.

536 *Acknowledgments*

537 We acknowledge all health-care workers involved in the diagnosis and treatment of
538 patients in Beijing Ditan Hospital, Capital Medical University.

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558 **References**

- 559 1. Fauci AS, Lane HC, Redfield RR. Covid-19 - Navigating the Uncharted. *N Engl J*
560 *Med.* 2020;382(13):1268-1269.
- 561 2. United States Centers for Disease Control and Prevention. Interim guidance on
562 the use of influenza antiviral agents during the 2010-2011 influenza season.
563 <http://www.cdc.gov/flu/professionals/antivirals/guidance/summary.html>. Accessed 20
564 Mar 2020.
- 565 3. Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the
566 Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019
567 (COVID-19). *Cureus.* 2020;12(4):e7560.
- 568 4. Guo X, Chen Y, Li X, Kong H, Yang S, Ye B, et al. Dynamic variations in the
569 peripheral blood lymphocyte subgroups of patients with 2009 pandemic H1N1
570 swine-origin influenza A virus infection. *Viol J.* 2011;8:215.
- 571 5. Nichols JE, Niles JA, Roberts NJ, Jr. Human lymphocyte apoptosis after
572 exposure to influenza A virus. *J Virol.* 2001;75(13):5921-5929.
- 573 6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and
574 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
575 China: a descriptive study. *Lancet.* 2020;395(10223):507-513.
- 576 7. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics
577 of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;382(18):1708-1720.
- 578 8. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia
579 predicts disease severity of COVID-19: a descriptive and predictive study. *Signal*
580 *Transduct Target Ther.* 2020;5(1):33.
- 581 9. National Health Commission of the People's Republic of China. Diagnosis and
582 Treatment Protocols for Patients with COVID-19 (Trial Version7, Revised).

- 583 <http://www.nhc.gov.cn/yzygj/s7652m/202003/a31191442e29474b98bfed5579d5a>
584 [f95.shtml](#). Accessed 16 July 2020.
- 585 10. National Health Commission of the People's Republic of China. Diagnosis and
586 Treatment Protocols for Patients with influenza (Version2019).
587 <http://www.nhc.gov.cn/yzygj/s7653p/201911/a577415af4e5449cb30ecc6511e369c7>.
588 [shtml](#). Accessed 16 July 2020.
- 589 11. World Health Orgazation. Clinical management of severe acute respiratory
590 infection when novel coronavirus (nCoV) infection is suspected: interim guidance.
591 Accessed at [https://www.who.int/publications-detail/clinical-management-of-severe-](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiraory-infection-whenovel-coronavirus-(ncov)-infection-is-suspected)
592 [acute-respiraory-infection-whenovel-coronavirus-\(ncov\)-infection-is-suspected](#).
593 Accessed 16 July 2020.
- 594 12. Wilhelm M. Influenza in older patients: a call to action and recent updates for
595 vaccinations. *Am J Manag Care*. 2018;24(2 Suppl):S15-S24.
- 596 13. World Health Organization. WHO-China joint mission on coronavirus disease
597 2019(COVID-19). Accessed at [https://www.who.int/news-room/feature-stories/detail/](https://www.who.int/news-room/feature-stories/detail/who-china-joint-mission-on-coronavirus-disease-2019)
598 [who-china-joint-mission-on-coronavirus-disease-2019](#). Accessed 28 Mar 2020.
- 599 14. Ozaras R, Cirpin R, Duran A, Duman H, Arslan O, Bakcan Y, et al. Influenza and
600 COVID-19 coinfection: Report of six cases and review of the literature. *J Med Virol*.
601 2020.doi: 10.1002/jmv.26125
- 602 15. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from
603 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet*
604 *Infect Dis*. 2020;20(4):425-434.
- 605 16. Chan MH, Wong VW, Wong CK, Chan PK, Chu CM, Hui DS, et al. Serum LD1
606 isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute
607 respiratory syndrome. *J Intern Med*. 2004;255(4):512-518.

- 608 17. Su R, Li Z, Wang Y, Liu Y, Zheng X, Gao C, et al. Imbalance between Th17 and
609 regulatory T cells in patients with systemic lupus erythematosus combined
610 EBV/CMV viraemia. *Clin Exp Rheumatol*. 2019. PMID: 31820723
- 611 18. Cheng Y, Zhao H, Song P, Zhang Z, Chen J, Zhou YH. Dynamic changes of
612 lymphocyte counts in adult patients with severe pandemic H1N1 influenza A. *J Infect
613 Public Health*. 2019;12(6):878-883.
- 614 19. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2
615 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci*.
616 2020;12(1):8.
- 617 20. Ko JH, Park GE, Lee JY, Lee JY, Cho SY, Ha YE, et al. Predictive factors for
618 pneumonia development and progression to respiratory failure in MERS-CoV
619 infected patients. *J Infect*. 2016;73(5):468-475.
- 620 21. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2
621 infection-a review of immune changes in patients with viral pneumonia. *Emerg
622 Microbes Infect*. 2020;9(1):727-732.
- 623 22. Sant AJ, McMichael A. Revealing the role of CD4(+) T cells in viral immunity. *J
624 Exp Med*. 2012;209(8):1391-1395.
- 625 23. He Z, Zhao C, Dong Q, Zhuang H, Song S, Peng G, et al. Effects of severe acute
626 respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes
627 and their subsets. *Int J Infect Dis*. 2005;9(6):323-330.
- 628 24. Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective.
629 *Expert Opin Pharmacother*. 2001;2(10):1671-1683.
- 630 25. O'Sullivan TE, Sun JC, Lanier LL. Natural Killer Cell Memory. *Immunity*.
631 2015;43(4):634-645.

632 26. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection:
633 the perspectives on immune responses. *Cell Death Differ.* 2020;27(5):1451-1454.

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

Table 1. Demographic and clinical characteristics of different study groups

Characteristics	Healthy Donors n=110	Non-severe COVID-19 n=80	Severe COVID-19 n=19	Severe influenza A n=43
Age groups (years), median (IQR)	45(34, 65)	37(30, 49)	67(53, 74)	70(64,83)
Gender N,(%)				
Male	53 (48.0)	41 (51.0)	15 (79.0)	30 (70.0)
Female	57 (52.0)	39 (49.0)	4 (21.0)	13 (30.0)
Admission time, median/ (IQR)		4 (2, 7)	5 (4.5, 10)	3 (2, 5)
Common Symptoms N,(%)				
Fever	/	58 (73.0)	19 (100.0)	43 (100.0)
Cough	/	38 (48.0)	19 (100.0)	43 (100.0)
Dyspnea	/	0	19 (100.0)	33(77.0)
Co-existing complications N,(%)				
Other	/	19 (24.0)	12 (63.0)	36 (84.0)

Hypertension	/	16 (20.0)	8 (42.0)	28 (65.0)
Diabetes	/	4 (5.0)	4 (21.0)	11 (26.0)
COPD	/	1 (1.0)	1 (5.0)	9 (21.0)
Cardiovascular disease	/	0	2 (11.0)	17 (40.0)
Renal disease	/	0	1 (5.0)	3 (7.0)
Autoimmune disorders	/	2 (3.0)	3 (16.0)	1 (2.0)
Outcome N,(%)				
Survival	/	80 (100.0)	18 (95.0)	39 (91.0)
Deaths	/	0	1 (5.0)	4 (9.0)

Abbreviations: COPD: Chronic obstructive pulmonary disease; IQR: Interquartile range

Table 2. Summary of comparison of cell counts of total WBCs, total lymphocytes, and lymphocyte subsets in patients with non-severe COVID-19, severe COVID-19, and severe influenza A with the first week of illness.

Parameters	I	II	III	IV	P value				
	Healthy Donors	Non-severe COVID-19	Severe COVID-19	Severe influenza A	I-II	I-III	I-IV	II-III	III-IV
WBC(*10 ⁹ /L), Median (IQR)	6.01 (5.02, 6.70)	5.34 (4.11, 6.10)	3.92 (3.30, 4.21)	5.99 (4.08, 8.10)	0.001	<0.0001	0.974	0.049	0.027
LY(*10 ⁹ /L), median (IQR)	1.78 (1.52, 2.16)	1.51 (1.12, 1.83)	0.93 (0.73, 1.07)	0.84 (0.57, 1.24)	0.027	<0.0001	<0.0001	<0.0001	0.528
NK cell count (cells/mm ³), median (IQR)	271 (151, 397)	192 (143, 361)	77 (57, 283)	–	0.514	0.355	–	0.346	–
B cell count (cells/mm ³), median (IQR)	–	203 (150, 299)	147 (89, 161)	–	–	–	–	0.093	–
T cell count (cells/mm ³), median (IQR)	1293 (1121, 1521)	1199 (907, 1521)	461 (429, 473)	550 (373, 550)	0.096	0.001	<0.0001	<0.0001	0.452

median (IQR)	1641)			749)					
CD4+ count	669			283					
(cells/mm ³),	(557,	680 (482,	288 (247,	(180,	0.116	0.001	<0.0001	0.001	0.686
median (IQR)	891)	817)	314)	418)					
CD8+ count	556			201					
(cells/mm ³),	(415,	421 (361,	144 (111,	(149,	0.036	0.001	<0.0001	0.001	0.163
median (IQR)	763)	701)	182)	303)					
CD4+/CD8+	1.23			1.37					
ratio, median	(0.97,	1.57 (1.02,	2.15 (1.45,	(1.01,	0.242	0.221	0.651	0.255	0.285
(IQR)	1.8)	1.86)	3.42)	1.97)					


Abbreviations: WBC: White blood cells, LY: Lymphocytes, IQR: Interquartile range;

$P < 0.05$ is statistically significant


Figure Legends

Fig. 1. Dynamic variations in cell counts of total WBCs, total lymphocytes, and lymphocyte subsets in patients with non-severe COVID-19, severe COVID-19, and severe influenza A at weeks (W) 1, 2, 3, and 4 during the course of illness.


(A–B) Box plots illustrating percentages of total WBCs and total lymphocytes in different groups at different times. Kruskal–Wallis test followed by Dunn’s multiple comparisons test or one-way analysis of variance (ANOVA) test followed by Tukey’s multiple comparisons test was performed to determine significant differences between the groups. **(C–H)** Box plots illustrating total cell counts of lymphocyte subsets in different groups at different times. Spearman’s nonparametric test was used to test for correlations. ** $P < 0.01$, *** $P < 0.001$ were considered significant.




A




B




C




D



E




F



medRxiv preprint doi: <https://doi.org/10.1101/2020.08.15.20175456>; this version posted August 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

G



H

